NCT06207812

Brief Summary

To follow up with all our participants with juvenile-onset mycosis fungoides, check on their status, and ask them or their parents about long term outcomes associated with their condition.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
20mo left

Started Jan 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Jan 2024Jan 2028

First Submitted

Initial submission to the registry

January 5, 2024

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 17, 2024

Completed
2 days until next milestone

Study Start

First participant enrolled

January 19, 2024

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 12, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 12, 2028

Last Updated

January 26, 2026

Status Verified

January 1, 2026

Enrollment Period

4 years

First QC Date

January 5, 2024

Last Update Submit

January 23, 2026

Conditions

Lymphomatoid PapulosisMycosis Fungoides

Outcome Measures

Primary Outcomes (1)

  • Safety and adverse events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

    Through study completion; an average of 1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants with juvenile-onset mycosis fungoides

You may qualify if:

  • To be eligible, participants had to be diagnosed with jMF or lyp before age 20. In the case of participants below the age of 18, parents and not the children will be contacted for participation (children are exempt from participation as their parents may answer our study questions).

You may not qualify if:

  • Participants older than 20 years of age at diagnosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Lymphomatoid PapulosisMycosis Fungoides

Condition Hierarchy (Ancestors)

Lymphoma, T-Cell, CutaneousLymphoma, T-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Julia Dai, MD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Julia Dai, MD

CONTACT

(713) 515-7961jdai6@mdanderson.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 5, 2024

First Posted

January 17, 2024

Study Start

January 19, 2024

Primary Completion (Estimated)

January 12, 2028

Study Completion (Estimated)

January 12, 2028

Last Updated

January 26, 2026

Record last verified: 2026-01

Locations

US(1)